U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H10I3N2O5.Na
Molecular Weight 665.9214
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM IOXITHALAMATE

SMILES

[Na+].CC(=O)NC1=C(I)C(C([O-])=O)=C(I)C(C(=O)NCCO)=C1I

InChI

InChIKey=PZTAFRMXSAAHMQ-UHFFFAOYSA-M
InChI=1S/C12H11I3N2O5.Na/c1-4(19)17-10-8(14)5(11(20)16-2-3-18)7(13)6(9(10)15)12(21)22;/h18H,2-3H2,1H3,(H,16,20)(H,17,19)(H,21,22);/q;+1/p-1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C12H10I3N2O5
Molecular Weight 642.9316
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ioxitalamic acid is a contrast media, which was used as a meglumine salt under the name Telebrix for intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography). The drug is no longer available on the market.

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8583
TELEBRIX

Approved Use

This medicinal product is for diagnostic use only. Contrast agent to be used for: intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography).
Diagnostic
Approved
8583
TELEBRIX

Approved Use

This medicinal product is for diagnostic use only. Contrast agent to be used for: intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography).
Diagnostic
Approved
8583
TELEBRIX

Approved Use

This medicinal product is for diagnostic use only. Contrast agent to be used for: intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography).
PubMed

PubMed

TitleDatePubMed
Resveratrol alleviates the cytotoxicity induced by the radiocontrast agent, ioxitalamate, by reducing the production of reactive oxygen species in HK-2 human renal proximal tubule epithelial cells in vitro.
2016-01
Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial.
2014
Computed microtomography visualization and quantification of mouse ischemic brain lesion by nonionic radio contrast agents.
2013-02
CT colonography with limited bowel preparation for the detection of colorectal neoplasia in an FOBT positive screening population.
2010-12
Ioxitalamate induces renal tubular apoptosis via activation of renal efferent nerve-mediated adrenergic signaling, renin activity, and reactive oxygen species production in rats.
2010-03
N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats.
2010
Telebrix Gastro in the management of adhesive small bowel obstruction.
2005-05
Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents.
2004-02
Telebrix: a better-tasting oral contrast agent for abdominal computed tomography.
1991-04
Patents

Patents

CN1803765 A
3

Sample Use Guides

In Vivo Use Guide
The recommended doses are 1.0 ml/kg (Intravenous urography); 1 and 1.8 ml/kg (computed tomography of brain and computed tomography of the whole body, respectively); 40 ml (ventriculography); 4-8 ml (coronary angiography). The solution for injection contains 350 mg iode/ml.
Route of Administration: Intravenous
In Vitro Use Guide
Ioxitalamic acid was added to human basophils and mast cells isolated from lung, skin, and heart tissue at concentration of 0.1 to 0.5 mol/L (Telebrix preparation). The drug induced histamine release from basophils and histamine and tryptase release from human heart mast cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:09:12 GMT 2025
Edited
by admin
on Mon Mar 31 18:09:12 GMT 2025
Record UNII
8P8Y8ZXJ8Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IOXITALAMATE SODIUM
WHO-DD  
Preferred Name English
SODIUM IOXITHALAMATE
Common Name English
Ioxitalamate sodium [WHO-DD]
Common Name English
BENZOIC ACID, 3-(ACETYLAMINO)-5-(((2-HYDROXYETHYL)AMINO)CARBONYL)-2,4,6-TRIIODO-, SODIUM SALT (1:1)
Systematic Name English
SODIUM IOXITALAMATE
Common Name English
ISOPHTHALAMIC ACID, 5-ACETAMIDO-N-(2-HYDROXYETHYL)-2,4,6-TRIIODO-, MONOSODIUM SALT
Systematic Name English
IOXITALAMIC ACID, SODIUM SALT
Common Name English
BENZOIC ACID, 3-(ACETYLAMINO)-5-(((2-HYDROXYETHYL)AMINO)CARBONYL)-2,4,6-TRIIODO-, MONOSODIUM SALT
Systematic Name English
TELEBRIX
Brand Name English
Code System Code Type Description
PUBCHEM
23681171
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
DRUG BANK
DBSALT002568
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
CAS
33954-26-6
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
EVMPD
SUB02760MIG
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
EPA CompTox
DTXSID10187573
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
FDA UNII
8P8Y8ZXJ8Y
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
SMS_ID
100000086432
Created by admin on Mon Mar 31 18:09:12 GMT 2025 , Edited by admin on Mon Mar 31 18:09:12 GMT 2025
PRIMARY
Related Record Type Details
Structure of IOXITALAMIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of IOXITALAMIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966